Abstract
We have reviewed the incidence of cisplatin-induced anaemia in patients affected with solid tumours treated with at least three courses of first-line cisplatin-containing regimens. In our experience, a low percentage (5%) of patients required transfusions of red blood cells. We think it is of the utmost importance to adopt uniform criteria in monitoring and treatment of patients at risk of developing cisplatin anaemia and to identify subsets of patients to eventually treat with erythropoietin.
MeSH terms
-
Anemia / chemically induced*
-
Anemia / drug therapy
-
Anemia / therapy
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects*
-
Erythrocyte Transfusion
-
Erythropoietin / administration & dosage
-
Erythropoietin / therapeutic use*
-
Evaluation Studies as Topic
-
Female
-
Humans
-
Incidence
-
Lung Neoplasms / drug therapy*
-
Male
-
Ovarian Neoplasms / drug therapy*
-
Prostatic Neoplasms / drug therapy*
-
Retrospective Studies
-
Risk Factors
Substances
-
Antineoplastic Agents
-
Erythropoietin
-
Cisplatin